COVID-19 and the Heart and Vasculature
Novel Approaches to Reduce Virus-Induced Inflammation in Patients With Cardiovascular Disease
The coronavirus disease 2019 (COVID-19) pandemic presents an unprecedented challenge and opportunity for translational investigators to rapidly develop safe and effective therapeutic interventions. Greater risk of severe disease in COVID-19 patients with comorbid diabetes mellitus, obesity, and heart disease may be attributable to synergistic activation of vascular inflammation pathways associated with both COVID-19 and cardiometabolic disease. This mechanistic link provides a scientific framework for translational studies of drugs developed for treatment of cardiometabolic disease as novel therapeutic interventions to mitigate inflammation and improve outcomes in patients with COVID-19.
Full text of this article can be found at: https://www.ahajournals.org/doi/10.1161/ATVBAHA.120.314513